Eli Lilly's Orforglipron Shows Promising Results in Phase 3 Diabetes Trials
Eli Lilly and Company has recently unveiled significant advancements regarding its investigational drug, orforglipron, which aims to revolutionize the management of type 2 diabetes. In two recent Phase 3 trials, known as ACHIEVE-2 and ACHIEVE-5, orforglipron demonstrated notable efficacy in lowering A1C levels, a primary indicator of blood sugar control, as well as leading to weight loss and improvements in cardiovascular risk factors.
In the ACHIEVE-2 trial, orforglipron was compared to dapagliflozin, a well-known SGLT-2 inhibitor, among adults struggling to manage their type 2 diabetes with metformin. The results revealed that orforglipron reduced A1C levels by up to 1.7%, substantially outperforming dapagliflozin’s reduction of only 0.8%. This trial marked a significant step, evidencing that orforglipron not only meets but exceeds the treatment expectations in a head-to-head comparison.
The ACHIEVE-5 trial offered additional promising insights, where orforglipron was assessed against a placebo in individuals with type 2 diabetes whose condition was inadequately controlled with insulin glargine. The trial showcased that orforglipron produced a further A1C reduction of 2.1% when paired with insulin therapy, marking it as a potentially transformative option for patients requiring advanced glycemic control strategies.
Remarkably, in both trials, all doses of orforglipron (3 mg, 12 mg, and 36 mg) met primary endpoints consistently, indicating its robust performance and safety profile. Participants of the trials reported only mild to moderate gastrointestinal-related adverse events that were generally manageable, with no significant safety concerns raised.
Jeff Emmick, M.D., Ph.D., Senior Vice President of Product Development at Lilly Cardiometabolic Health, emphasized the importance of these results: "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes."
As the trials progress, future detailed results will be presented at medical conferences and published in peer-reviewed journals. Lilly anticipates that regulatory submissions for orforglipron will commence in 2026, aligning with global health standards. The ongoing Phase 3 clinical programs, having enrolled over 6,000 participants since their inception in 2023, aim to establish orforglipron as a new cornerstone in diabetes care.
Besides type 2 diabetes, orforglipron is also being explored for other indications including obesity, obstructive sleep apnea, hypertension, and even osteoarthritis pain, showcasing its vast potential in addressing multiple health challenges. The compound, which Lilly licensed from Chugai Pharmaceutical Co., Ltd. in 2018, represents a novel class of medication as a once-daily, oral GLP-1 receptor agonist, distinguished by its flexibility in administration.
Anticipation builds within the medical community for the ACHIEVE-4 trial, expected to finalize results in early 2026, which will bolster the understanding of orforglipron’s full capabilities. As Eli Lilly continues to innovate, the focus remains steadfast on improving the quality of life for individuals grappling with chronic health conditions and redefining standards in diabetes treatment.
In the ACHIEVE-2 trial, orforglipron was compared to dapagliflozin, a well-known SGLT-2 inhibitor, among adults struggling to manage their type 2 diabetes with metformin. The results revealed that orforglipron reduced A1C levels by up to 1.7%, substantially outperforming dapagliflozin’s reduction of only 0.8%. This trial marked a significant step, evidencing that orforglipron not only meets but exceeds the treatment expectations in a head-to-head comparison.
The ACHIEVE-5 trial offered additional promising insights, where orforglipron was assessed against a placebo in individuals with type 2 diabetes whose condition was inadequately controlled with insulin glargine. The trial showcased that orforglipron produced a further A1C reduction of 2.1% when paired with insulin therapy, marking it as a potentially transformative option for patients requiring advanced glycemic control strategies.
Remarkably, in both trials, all doses of orforglipron (3 mg, 12 mg, and 36 mg) met primary endpoints consistently, indicating its robust performance and safety profile. Participants of the trials reported only mild to moderate gastrointestinal-related adverse events that were generally manageable, with no significant safety concerns raised.
Jeff Emmick, M.D., Ph.D., Senior Vice President of Product Development at Lilly Cardiometabolic Health, emphasized the importance of these results: "Orforglipron has now demonstrated superiority over two active comparators in clinical trials for type 2 diabetes."
As the trials progress, future detailed results will be presented at medical conferences and published in peer-reviewed journals. Lilly anticipates that regulatory submissions for orforglipron will commence in 2026, aligning with global health standards. The ongoing Phase 3 clinical programs, having enrolled over 6,000 participants since their inception in 2023, aim to establish orforglipron as a new cornerstone in diabetes care.
Besides type 2 diabetes, orforglipron is also being explored for other indications including obesity, obstructive sleep apnea, hypertension, and even osteoarthritis pain, showcasing its vast potential in addressing multiple health challenges. The compound, which Lilly licensed from Chugai Pharmaceutical Co., Ltd. in 2018, represents a novel class of medication as a once-daily, oral GLP-1 receptor agonist, distinguished by its flexibility in administration.
Anticipation builds within the medical community for the ACHIEVE-4 trial, expected to finalize results in early 2026, which will bolster the understanding of orforglipron’s full capabilities. As Eli Lilly continues to innovate, the focus remains steadfast on improving the quality of life for individuals grappling with chronic health conditions and redefining standards in diabetes treatment.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.